Empagliflozin

Indication

Monotherapy for treating type 2 diabetes (NICE TA390)

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Green

Brand:

Jardiance®

Nice TA:

390

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Endocrine system

Background

Canagliflozin, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:

a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
a sulfonylurea or pioglitazone is not appropriate.

The LSCMMG recommends empagliflozin as a 1^st line ““gliflozin””.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Green	Green	Green	Green	Green	Green	Green	Green

What do the colours mean?

Last Updated: 01 - Jun - 2016